Cardiff Oncology (NASDAQ: CRDF) CFO awarded 486,650 stock options
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
Cardiff Oncology, Inc. reported that Chief Financial Officer Joshua B. Muntner received a grant of 486,650 stock options to purchase common stock at an exercise price of $1.58 per share. These options expire on April 6, 2036 and are held directly.
According to the vesting schedule, 121,663 options vest on April 6, 2027, and 10,139 options vest monthly for 36 months after that date. Following this award, Muntner holds a total of 487,150 stock options linked to Cardiff Oncology common stock.
Positive
- None.
Negative
- None.
Insights
CFO receives a sizable, routine stock option grant with long-term vesting.
Chief Financial Officer Joshua B. Muntner was granted 486,650 stock options with a $1.58 exercise price, expiring on April 6, 2036. This is a compensation-related award, not an open-market purchase or sale, so it carries limited trading signal.
The options vest over time, with 121,663 vesting on April 6, 2027 and 10,139 vesting monthly for 36 months thereafter. This multi-year schedule is designed to align the CFO’s incentives with longer-term company performance, while spreading potential dilution over several years.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Muntner Joshua B
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 486,650 | $0.00 | -- |
Holdings After Transaction:
Stock Options — 487,150 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 486,650 options
Exercise price: $1.58 per share
Options post-transaction: 487,150 options
+3 more
6 metrics
Options granted
486,650 options
Stock options awarded on April 6, 2026
Exercise price
$1.58 per share
Exercise price for granted stock options
Options post-transaction
487,150 options
Total stock options held after grant
Initial vesting tranche
121,663 options
Vesting on April 6, 2027
Monthly vesting amount
10,139 options
Vest monthly for 36 months after April 6, 2027
Option expiration
April 6, 2036
Expiration date of granted options
Key Terms
Stock Options, exercise price, expiration date, vest, +1 more
5 terms
Stock Options financial
"security_title: Stock Options"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"conversion_or_exercise_price: 1.5800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-04-06T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"121,663 vest on April 6, 2027 and 10,139 vest monthly"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
FAQ
What did Cardiff Oncology (CRDF) disclose about its CFO in this Form 4/A?
Cardiff Oncology disclosed a new stock option grant to its CFO. Chief Financial Officer Joshua B. Muntner received 486,650 stock options with a $1.58 exercise price, expiring in 2036, as part of his equity compensation rather than an open-market share purchase or sale.
How many Cardiff Oncology (CRDF) stock options were granted to the CFO?
The CFO received 486,650 stock options linked to common stock. These options give him the right to buy 486,650 Cardiff Oncology shares at a fixed $1.58 exercise price, subject to the vesting schedule and the April 6, 2036 expiration date disclosed.
What is the exercise price and expiration date of the CRDF options granted?
The granted options have a $1.58 exercise price and expire in 2036. Specifically, the stock options let the CFO purchase Cardiff Oncology common shares at $1.58 per share, with the options expiring on April 6, 2036 if they are not exercised before that date.
How do the new CRDF stock options vest for Cardiff Oncology’s CFO?
The options vest over several years starting in 2027. Cardiff Oncology disclosed that 121,663 options vest on April 6, 2027, and an additional 10,139 options vest each month for 36 months afterward, creating a long-term incentive structure for the CFO.
How many Cardiff Oncology (CRDF) stock options does the CFO hold after this grant?
After the grant, the CFO holds 487,150 stock options in total. The Form 4/A shows this post-transaction figure, indicating his aggregate option position tied to Cardiff Oncology common stock following the 486,650-option award.